Make Hay While the Sun Shines When it Comes to Edwards Lifesciences' Stock

It's that time of year again when public companies report their quarterly results, hoping that the tales they spin would buoy their stock higher.

Or manage disappointing results so the resulting sell-off doesn't sting.

On July 25, Edwards Lifesciences will report its quarterly results. Edwards, still the only company in the U.S. to have a FDA- approved, commercially available Sapien line of transcatheter aortic valves, has reported disappointing sales of the product for several quarters. In fact So far, the Irvine, California company's stock has declined 26.6% this year. The stock took a nosedive after the last earnings call. 

But now Glenn Novarro, senior analyst at RBC Capital Markets, believes the tide is about to turn - albeit temporarily. 

In a research note published Monday, Novarro essentially said that investors looking to make money on the stock should act now.

The "recent survey" points to a survey of 20 physicians that RBC Capital Markets conducted to gauge the adoption of Sapien at various medical centers in the U.S. That survey indicated that sales of the product increased roughly 20 percent in the second quarter of the year from the first quarter of 2013. 

That means once Edwards reports it results - with that expected bump up in Sapien sales - the stock will see some upside. But it will not last, is Novarro's opinion.

And that's because competitors are catching up both in the U.S. and Europe. Here's more of what Novarro wrote:

All of this means only one thing: When it comes to making money by trading Edwards' stock, make hay while the sun shines. 

[Photo Credit: iStockPhoto.com user ru_]

-- By Arundhati Parmar, Senior Editor, MD+DI